Canadian biopharmaceutical company Therapure Biopharma, Inc., has filed a preliminary prospectus with securities regulatory authorities in each of the provinces and territories of Canada in connection with a proposed initial public offering of its common shares.
The offering is being made through a syndicate of underwriters co-led by GMP Securities L.P., CIBC World Markets Inc. and National Bank Financial Inc.
Mississauga-based Therapure focuses on manufacturing complex biologics for its customers and on developing, manufacturing and selling its own blood and plasma-related therapeutic products.
It operates three divisions:
– Therapure Biomanufacturing, a contract development and manufacturing division;
– Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA™ technology to develop a portfolio of plasma-derived pharmaceutical products; and
– Therapure Innovations, a proprietary therapeutics and platform technologies research and development division.
The company operates out of two facilities in Mississauga: a 130,000 sq. ft. cGMP facility that includes biomanufacturing, research and quality control laboratories and is built to meet FDA (US), HPFB (Canada), EMA (Europe) and MHRA (UK) standards, and a new 43,000 sq. ft. facility housing 30,000 sq. ft. of cGMP warehouse.